ATE527285T1 - Anti-muc1-alpha-beta-antikörper - Google Patents

Anti-muc1-alpha-beta-antikörper

Info

Publication number
ATE527285T1
ATE527285T1 AT06734050T AT06734050T ATE527285T1 AT E527285 T1 ATE527285 T1 AT E527285T1 AT 06734050 T AT06734050 T AT 06734050T AT 06734050 T AT06734050 T AT 06734050T AT E527285 T1 ATE527285 T1 AT E527285T1
Authority
AT
Austria
Prior art keywords
muc1
alpha beta
beta antibodies
antibodies
alpha
Prior art date
Application number
AT06734050T
Other languages
English (en)
Inventor
Daniel Rubinstein
Daniel Wreschner
Original Assignee
Univ Ramot
Biomodifying Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot, Biomodifying Llc filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE527285T1 publication Critical patent/ATE527285T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT06734050T 2005-01-28 2006-01-27 Anti-muc1-alpha-beta-antikörper ATE527285T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64787005P 2005-01-28 2005-01-28
PCT/US2006/003213 WO2006081553A2 (en) 2005-01-28 2006-01-27 ANTI-MUC1 α/ß ANTIBODIES

Publications (1)

Publication Number Publication Date
ATE527285T1 true ATE527285T1 (de) 2011-10-15

Family

ID=36741145

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06734050T ATE527285T1 (de) 2005-01-28 2006-01-27 Anti-muc1-alpha-beta-antikörper

Country Status (8)

Country Link
US (2) US20080226619A1 (de)
EP (1) EP1848804B1 (de)
JP (1) JP2008528623A (de)
CN (1) CN101175855A (de)
AT (1) ATE527285T1 (de)
AU (1) AU2006209246A1 (de)
CA (1) CA2595778A1 (de)
WO (1) WO2006081553A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007298494B2 (en) * 2006-09-21 2013-09-26 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
CN104634974B (zh) * 2009-03-05 2017-08-08 独立行政法人产业技术综合研究所 肝内胆管癌的检出、辨别方法
WO2012173228A1 (ja) * 2011-06-16 2012-12-20 国立大学法人東京工業大学 ３´硫酸化コア１糖鎖に結合するプローブを用いるムチン１の分析方法、及び乳癌の検出又はモニタリング方法
WO2013023162A2 (en) * 2011-08-10 2013-02-14 Genus Oncology, Llc Anti-muc1 antibodies for cancer diagnostics
US10369104B2 (en) * 2014-04-01 2019-08-06 Children's Hospital Los Angeles Targeted polymerized nanoparticles for cancer treatment
RU2652901C1 (ru) * 2016-12-23 2018-05-03 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Нижегородский государственный университет им. Н.И. Лобачевского" Антитела, связывающие опухолеассоциированный MUC1, и способы их получения
HRP20240756T1 (hr) * 2018-05-18 2024-09-13 Daiichi Sankyo Co., Ltd. Anti-muc1-eksatekan antitijelo-lijek konjugat
KR20220161267A (ko) * 2020-03-18 2022-12-06 바이오모디파잉, 엘엘씨 항-muc1-sea 항체
US20250041437A1 (en) 2023-07-31 2025-02-06 Sun Pharma Advanced Research Company Limited Humanized muc1 antibody and antibody drug conjugate

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
IL110464A0 (en) * 1994-07-26 1994-10-21 Univ Ramot Novel proteins for the diagnosis, imaging, and therapy of human cancer
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
GB9904695D0 (en) 1999-03-01 1999-04-21 Imp Cancer Res Tech Peptide
US6716966B1 (en) * 1999-08-18 2004-04-06 Altarex Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
DE60018761T2 (de) * 1999-08-18 2006-02-02 Altarex Medical Corp., Edmonton Therapeutischer antikörper gegen das muc-1-antigen und verfahren zu dessen verwendung
JP2003533181A (ja) * 2000-02-01 2003-11-11 ジ・オースティン・リサーチ・インスティテュート ムチン−１誘導抗原および免疫療法におけるその使用
WO2001070265A2 (en) * 2000-03-24 2001-09-27 Biomira, Inc. Lipopeptide adjuvants
JP2004500828A (ja) * 2000-03-30 2004-01-15 ダイアックス　コーポレーション Ｍｕｃｉｎ−１特異的結合メンバー及びその使用方法
AU9263101A (en) * 2000-09-11 2002-03-26 Donald W Kufe Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
EP2241887B1 (de) * 2000-11-27 2015-01-14 Minerva Biotechnologies Corporation Diagnostika, Drogenscreening und Behandlung für Krebs
EP1958642A1 (de) * 2000-12-22 2008-08-20 Dana-Farber Cancer Institute Regulierung des Zellwachstums durch MUC1
US20050019324A1 (en) * 2001-03-29 2005-01-27 Wreschner Daniel H. Peptides and antibodies to muc 1 proteins
EP1383802A4 (de) * 2001-03-30 2005-08-03 Univ California Anti-muc-1-einzelkettenantikörper zum targeting von tumoren
US7183388B2 (en) * 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
WO2003031569A2 (en) * 2001-10-10 2003-04-17 Centocor, Inc. Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
US6716627B2 (en) * 2001-12-20 2004-04-06 Isis Pharmaceuticals, Inc. Antisense modulation of mucin 1, transmembrane expression
US20060069238A1 (en) * 2002-04-15 2006-03-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
AU2003228067B2 (en) 2002-04-22 2008-05-29 Recopharma Ab Mucin fusion polypeptide vaccines, compositions and methods of use thereof
JP2006504630A (ja) * 2002-04-22 2006-02-09 ダイアックス コーポレイション ムチンポリペプチドに特異的な抗体
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
DK1511768T3 (da) * 2002-06-11 2007-08-20 Glaxosmithkline Biolog Sa Immunogene sammensætninger
CN101824090B (zh) * 2002-06-14 2013-01-02 免疫医疗公司 人源化单克隆抗体hPAM4
RU2005100777A (ru) * 2002-06-14 2005-08-27 Иммуномедикс, Инк. (Us) Моноклональное антитело рам4 и его применение для диагностики и лечения рака поджелудочной железы
CA2491017A1 (en) * 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
EP1764372B1 (de) 2005-09-20 2009-08-12 Peter Jon Nelson Gewebeinhibitor für Metalloproteinasen (TIMP) gebunden an ein Glycosylphosphatidylinositol (GPI-) Anker zur Behandlung von Krebs

Also Published As

Publication number Publication date
CN101175855A (zh) 2008-05-07
JP2008528623A (ja) 2008-07-31
WO2006081553A2 (en) 2006-08-03
US20120207772A1 (en) 2012-08-16
EP1848804B1 (de) 2011-10-05
US20080226619A1 (en) 2008-09-18
US8648172B2 (en) 2014-02-11
CA2595778A1 (en) 2006-08-03
AU2006209246A1 (en) 2006-08-03
EP1848804A2 (de) 2007-10-31
EP1848804A4 (de) 2009-05-13
WO2006081553A3 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
TW200732349A (en) Anti-OX40L antibodies and methods using same
CR20120371A (es) Antagonistas de pcsk9
DE602006013029D1 (de) Anti-egfr-antikörper
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
SV2011003834A (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
WO2010011944A3 (en) Protein screeing methods
WO2007115837A3 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
EA200702643A1 (ru) Антитела, связывающие tweak
CL2011000010A1 (es) Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende.
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
JO3775B1 (ar) جزيئات رابطة لليمفو بويتين اللحمية بالغدة الصعترية أو الثيمية (tslp) وطرق لاستخدام تلك الجزيئات
WO2006096489A3 (en) Anti-m-csf antibody compositions having reduced levels of endotoxin
MX2009004167A (es) Anticuerpos que enlazan epitopos cxcr7.
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
ECSP088743A (es) Anticuerpos para egfl7 y métodos para su uso
ATE546524T1 (de) Verfahren zur herstellung aktiver scfv-antikörper und bibliotheken dafür
EP1848804A4 (de) Anti-muci-alpha-beta-antikörper
WO2010009856A3 (en) Goodpasture antigen binding protein and its detection
WO2006076497A3 (en) Osplation of pathogenic prions
ATE417816T1 (de) Anilinohexafluoroisopropanol verbindungen
CY1115900T1 (el) Αντισωματα αντι-ephb4 και μεθοδοι χρησης αυτων

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties